What did @botoxbosschi actually say?
This is a fairly standard Botox consultation and injection walkthrough. The injector marks units directly on the patient's forehead, recommends 15 units instead of a "typical" 20 for a first-timer, discusses freezing versus natural movement, and adds crow's feet treatment at 2.5 units per marking. She also mentions releasing the "under eye" area with Botox. The framing is educational and patient-facing, which matters because viewers will walk away with specific unit numbers in their heads.
The video is not making wild claims about peptides or longevity. It is a procedural demonstration. But that does not mean everything said is accurate or without risk, particularly the under-eye comment.
Does the science back this up?
Mostly yes, with one real exception. The forehead and glabellar dosing she describes is consistent with published ranges. Carruthers and Carruthers (2003, Dermatologic Surgery) established that glabellar complex treatments typically fall in the 20-40 unit range for onabotulinumtoxinA, and lighter doses for first-time patients are well-supported in practice. Going to 15 units for a patient with minimal lines is reasonable clinical judgment, not recklessness.
The crow's feet dosing of 2.5 units per injection site also tracks with the literature. A 2016 randomized trial by Monheit et al. in Dermatologic Surgery found 12 units per side effective, and smaller doses per site are standard for patients seeking natural-looking results.
The under-eye claim is where the evidence gets thin. Injecting Botox below the orbital rim to "release" the under-eye area is an off-label use with a narrow safety margin and documented risks including ectropion and worsening of festoons in some patients (Fagien, 2010, Plastic and Reconstructive Surgery).
What did they get wrong (or right)?
Credit where it is due: the injector handled the freeze-versus-movement conversation well. Asking the patient "do you prefer to still have movement in your forehead or do you want it fairly frozen" is exactly the kind of shared decision-making that reduces patient dissatisfaction. Research on patient-reported outcomes in aesthetic medicine consistently ties dissatisfaction to unmet movement expectations, not to the toxin itself.
The unit-per-marking system she uses is practical and transparent. Patients can see what they are getting, which is better than vague volume-based dosing language.
What she glossed over is the under-eye injection. Saying she will "release this a tiny bit" without explaining that this is an advanced, off-label technique with real risks is a gap. For a video tagged as educational, that omission matters. Viewers with festoons or significant lower eyelid laxity who see this and request it from an inexperienced injector could end up with complications. She is not wrong to offer it, but she is wrong to frame it as routine.
What should you actually know?
Botox unit counts are not universal. OnabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), and incobotulinumtoxinA (Xeomin) are measured in different units that are not interchangeable one-to-one. If a provider quotes you units without specifying the product, ask. A Dysport "unit" is not the same as a Botox unit, and dosing confusion is a real source of over-treatment.
Forehead treatment also carries a specific risk this video did not mention: ptosis, or drooping of the eyelid or brow. It is uncommon but not rare, occurring in roughly 1-5% of forehead treatments depending on injection technique and patient anatomy (Naumann et al., 2008, Journal of Neurology). A lighter dose reduces but does not eliminate this risk.
The under-eye area is genuinely advanced. If a provider suggests it for your first treatment, it is reasonable to ask about their specific training and complication rate for that technique.